B

Bavarian Nordic A/S
CSE:BAVA

Watchlist Manager
Bavarian Nordic A/S
CSE:BAVA
Watchlist
Price: 198.4 DKK 3.09% Market Closed
Market Cap: 15.6B DKK
Have any thoughts about
Bavarian Nordic A/S?
Write Note

Bavarian Nordic A/S
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bavarian Nordic A/S
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
B
Bavarian Nordic A/S
CSE:BAVA
Interest Income Expense
kr93.2m
CAGR 3-Years
N/A
CAGR 5-Years
56%
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Interest Income Expense
kr1.6B
CAGR 3-Years
643%
CAGR 5-Years
53%
CAGR 10-Years
65%
Zealand Pharma A/S
CSE:ZEAL
Interest Income Expense
kr119.1m
CAGR 3-Years
N/A
CAGR 5-Years
36%
CAGR 10-Years
45%
Ascendis Pharma A/S
NASDAQ:ASND
Interest Income Expense
-€126.9m
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
-73%
F
Fluoguide AS
STO:FLUO
Interest Income Expense
kr47k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Interest Income Expense
kr558k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Bavarian Nordic A/S
Glance View

Market Cap
15.5B DKK
Industry
Biotechnology

Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The firm is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.

BAVA Intrinsic Value
168.42 DKK
Overvaluation 15%
Intrinsic Value
Price
B

See Also

What is Bavarian Nordic A/S's Interest Income Expense?
Interest Income Expense
93.2m DKK

Based on the financial report for Jun 30, 2024, Bavarian Nordic A/S's Interest Income Expense amounts to 93.2m DKK.

What is Bavarian Nordic A/S's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
56%

Back to Top